CD38 and Miyoshi myopathy: Nevertheless, a subpopulation of CD38+ Treg was found to be more immunosuppressive than CD38− Treg and decreased in patients treated with daratumumab, suggesting an additional mechanism of action for this anti-CD38 antibody used to treat MM patients [53].